RNS Number:6668H
Gyrus Group PLC
19 February 2003

19 February 2003



           GYRUS GROUP PLC ANNOUNCES THE RESULTS OF COSMETIC
                               SURGERY TRIALS



READING, UK - Gyrus Group PLC, (GYG.L "Gyrus" or "the Group") a world leader in
the surgical management of tissue using less traumatic techniques, announces the
results of trials conducted on its PlasmaKinetic(R) II ("PKII") technology for
use in cosmetic surgery.



- A single-blind randomised case control pilot trial on the treatment of benign
skin lesions conducted in the UK, met the objectives of demonstrating the same
efficacy and low complication rate as use of a Carbon Dioxide Laser.



- The pre-clinical study in the US concluded that PKII may have the ability to
produce a significant clinical effect with a more rapid healing time compared to
Carbon Dioxide Laser.  This result now needs to be validated in the treatment of
sun-damaged, wrinkled, facial skin.



- A protocol for treating sun-damaged skin has been submitted in the UK and
further submissions will now also be made at key US investigator sites.



- The results of these studies will be presented at the American Society for
Laser Medicine and Surgery (ASLMS) Meeting in Anaheim, CA, in April 2003.



"These results are very encouraging and we now need to assess whether the
potential benefits of our technology are transferable to the target applications
of treating the facial effects of sun-damage as well as other cosmetic 
blemishes", said Mark Goble, Gyrus Group Managing Director.



Notes to editors



About Gyrus

Gyrus Group PLC is a growing medical technology company with principal UK
operations based in Cardiff and Reading. The Group comprises four operational
units: Gyrus Medical Inc. (Minneapolis), Gyrus Medical Ltd. (Cardiff), Gyrus
International Ltd. (Reading) and Gyrus ENT (Memphis).



Enquiries:


Gyrus Group PLC
Mark Goble, Managing Director                                  Tel: 01189 219720
Tom Murphy, Finance Director

Financial Dynamics                                            Tel: 0207 831 3113
Ben Atwell




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGUURGPUPWGMR